<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03553433</url>
  </required_header>
  <id_info>
    <org_study_id>DER-USZ-AAN-021</org_study_id>
    <nct_id>NCT03553433</nct_id>
  </id_info>
  <brief_title>Apremilast Treatment for Pruritus and Quality of Life in Scalp Psoriasis</brief_title>
  <acronym>APRESCALP</acronym>
  <official_title>A Phase 4 Multicenter, Randomized, Placebo-controlled Study Evaluating the Effect of Apremilast on Pruritus and Quality of Life of Patients With Moderate-to-severe Scalp Psoriasis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Zurich</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Zurich</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A phase 4 multicenter, randomized, placebo-controlled Study evaluating the Effect of
      Apremilast on Pruritus and Quality of Life of Patients with moderate-to-severe Scalp
      Psoriasis
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The scalp is the most frequently affected body region in psoriasis. Scalp Psoriasis can
      impair the quality of life greatly due to pruritus. This is however not usually investigated
      as a primary outcome of treatments.

      This study will investigate the effects of apremilast on the pruritus and quality of life and
      other patient reported outcomes in patients with scalp psoriasis.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Not yet recruiting</last_known_status>
  <start_date type="Anticipated">June 2018</start_date>
  <completion_date type="Anticipated">June 2020</completion_date>
  <primary_completion_date type="Anticipated">December 2019</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
    <masking_description>Double-blind</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Scalp VAS Pruritus assessment</measure>
    <time_frame>Weeks 16</time_frame>
    <description>Pruritus VAS Scale (0 - 100)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Scalp VAS Pruritus assessment</measure>
    <time_frame>Weeks 0, 4, 32, 52</time_frame>
    <description>Pruritus VAS Scale (0 - 100)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>% BSA</measure>
    <time_frame>Weeks 0, 4, 16, 32, 52</time_frame>
    <description>Body surface area</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>% BSA of scalp</measure>
    <time_frame>Weeks 0, 4, 16, 32, 52</time_frame>
    <description>Body surface area of scalp</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PrecisePASI</measure>
    <time_frame>Weeks 0, 4, 16, 32, 52</time_frame>
    <description>Psoriasis Area and Severity Index, modified to measure in percentages</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PGA</measure>
    <time_frame>Weeks 0, 4, 16, 32, 52</time_frame>
    <description>Physicians Global Assessment (0 - 5)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Scalp-PGA</measure>
    <time_frame>Weeks 0, 4, 16, 32, 52</time_frame>
    <description>Physicians Global Assessment of the Scalp (0 - 5)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>DLQI</measure>
    <time_frame>Weeks 0, 4, 16, 32, 52</time_frame>
    <description>Skin related Quality of life (0 to 30)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Scalpdex</measure>
    <time_frame>Weeks 0, 4, 16, 32, 52</time_frame>
    <description>23 items related to scalp symptoms</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PSSI</measure>
    <time_frame>Weeks 0, 4, 16, 32, 52</time_frame>
    <description>Psoriasis score measuring intensity on the scalp</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>VAS pruritus assessment</measure>
    <time_frame>Weeks 0, 4, 16, 32, 52</time_frame>
    <description>Pruritus VAS Scale (0 - 100)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>EQ-5D</measure>
    <time_frame>Weeks 0, 4, 16, 32, 52</time_frame>
    <description>Health-related Quality of Life Instrument</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">90</enrollment>
  <condition>Psoriasis of Scalp</condition>
  <condition>Psoriasis Vulgaris</condition>
  <arm_group>
    <arm_group_label>Verum</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Apremilast 30mg bd</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo Oral Tablet</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Excipiens</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Apremilast 30mg</intervention_name>
    <description>Anti-psoriatic drug</description>
    <arm_group_label>Verum</arm_group_label>
    <other_name>Otezla</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo Oral Tablet</intervention_name>
    <description>Indistinguishable tablets not containing apremilast, Placebo Oral Tablet</description>
    <arm_group_label>Placebo Oral Tablet</arm_group_label>
    <other_name>Placebo</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:

          1. Adult (&gt;18yrs);

          2. Signed informed consent

          3. Clinical diagnosis of chronic plaque psoriasis for at least 3 months as determined by
             the subject's medical history and confirmation of diagnosis through physical
             examination by the Investigator;

          4. Psoriatic lesions with DLQI &gt;10 and involvement of &gt;20% of the scalp and pruritus with
             a VAS score of &gt; 50 (0-100);

          5. Candidate for systemic therapy;

          6. Females who are of child-bearing potential should be practicing birth control
             throughout the study and for 70 days after the last dose of study drug;

          7. Subject is judged to be in good health as determined by the Investigator based upon
             the results of medical history, laboratory profile and physical examination.

          8. Creatinine &lt; 80 umol/l at Inclusion

        Exclusion criteria:

          1. Erythrodermic Ps, medication-induced or medication-exacerbated Ps or new onset guttate
             Ps or other skin conditions at the time of the screening visit (e.g. eczema) that
             would interfere with evaluations of the effect of the investigational product on Ps;

          2. Use of any anti-psoriatic therapy last administered less than 4 weeks of start of
             study drug such as

               1. Three months or 5 PK half-lives, whichever is longer, for biologics tumor
                  necrosis factor (TNF) antagonists, interleukin (IL) 12/23/17 inhibitors or other
                  biologic drugs

               2. 4 weeks for immunosuppressive / -modulating drugs including cyclosporine A,
                  methotrexate, azathioprine, mycophenolate mofetil, fumaric acid esters,
                  retinoids, JAK inhibitors, corticosteroids, any other experimental drug, etc.

               3. Topical medications (eg. Corticosteroids) except coal tar shampoo, and/or
                  salicylic acid scalp preparations on scalp lesions.

               4. 4 weeks for phototherapy (ie, UVB, PUVA).

          3. Infection(s) requiring treatment with intravenous (IV) anti-infectives within 30 days
             prior to the Baseline visit or oral anti-infectives within 14 days prior to the
             Baseline visit;

          4. Positive serology for hepatitis B, hepatitis C, HIV indicating acute or chronic
             infection;

          5. Chronic recurring bacterial infections or active TB;

          6. Positive pregnancy test at Screening or at the Baseline visit;

          7. Female subjects who are pregnant or breast-feeding or considering becoming pregnant
             during the study;

          8. History of clinically significant alcohol or drug abuse in the last 12 months;

          9. Known hypersensitivity to the excipients of OtezlaÂ® as stated in the label;

         10. Subject is considered by the Investigator, for any reason, to be an unsuitable
             candidate for the study.

         11. Prior history of suicide attempt at any time in the subject's life time prior to
             signing the informed consent and randomization, or major psychiatric illness requiring
             hospitalization within the last 3 years prior to signing the informed consent.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Alexander Navarini, MD PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Zurich</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Alexander Navarini, MD PhD</last_name>
    <phone>0041442551111</phone>
    <email>alexander.navarini@usz.ch</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Karolina Papageorgiou, MD</last_name>
    <phone>0041442551111</phone>
    <email>karolina.papageorgiou@usz.ch</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>KSSG</name>
      <address>
        <city>Saint Gallen</city>
        <state>SG</state>
        <country>Switzerland</country>
      </address>
    </facility>
    <contact>
      <last_name>Antonio Cozzio, MD PhD</last_name>
      <phone>+41 71 494 20 30</phone>
      <email>antonio.cozzio@kssg.ch</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Inselspital</name>
      <address>
        <city>Bern</city>
        <country>Switzerland</country>
      </address>
    </facility>
    <contact>
      <last_name>Nikhil Yawalkar, MD</last_name>
      <phone>+41 (31) 632 22 88</phone>
      <email>nikhil.yawalkar@insel.ch</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHUV</name>
      <address>
        <city>Lausanne</city>
        <country>Switzerland</country>
      </address>
    </facility>
    <contact>
      <last_name>Curdin Conrad, MD</last_name>
      <phone>+41 21 314 0400</phone>
      <email>curdin.conrad@chuv.ch</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Department of Dermatology, University Hospital Zurich</name>
      <address>
        <city>Zurich</city>
        <zip>8091</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Switzerland</country>
  </location_countries>
  <verification_date>June 2018</verification_date>
  <study_first_submitted>April 18, 2018</study_first_submitted>
  <study_first_submitted_qc>June 11, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">June 12, 2018</study_first_posted>
  <last_update_submitted>June 11, 2018</last_update_submitted>
  <last_update_submitted_qc>June 11, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">June 12, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>apremilast</keyword>
  <keyword>quality of life</keyword>
  <keyword>pruritus</keyword>
  <keyword>oral drug</keyword>
  <keyword>placebo</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Psoriasis</mesh_term>
    <mesh_term>Pruritus</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Apremilast</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

